SAN
JOSE, Calif., Oct. 3, 2023
/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the
"Company") (NASDAQ: ANIX), a biotechnology company focused on the
treatment and prevention of cancer, today announced that the U.S.
Patent and Trademark Office (USPTO) has issued U.S. Patent Number
11,786,489, which broadens protection of Anixa's novel ovarian
cancer vaccine technology.
The patent, titled "Ovarian Cancer Vaccines", was invented by
the late Dr. Vincent Tuohy of
Cleveland Clinic and covers nucleic acid-based delivery of the
vaccine. Anixa exclusively licensed the technology from Cleveland
Clinic and is developing the technology in partnership with the
not-for-profit, multispecialty academic medical center.
Dr. Amit Kumar, Chairman and CEO
of Anixa, stated, "We are delighted to receive this patent from the
USPTO as it broadens protection of our novel ovarian cancer vaccine
technology. We are looking forward to continuing our preclinical
work on the vaccine with support from the National Cancer
Institute's PREVENT Program, a peer-reviewed program designed to
support development of the best ideas in cancer prevention."
Anixa's ovarian cancer vaccine targets the extracellular domain
of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed
in the ovaries but disappears as a woman reaches and advances
through menopause. However, AMHR2-ED is expressed again in the
majority of ovarian cancers.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic portfolio
consists of an ovarian cancer immunotherapy program being developed
in collaboration with Moffitt Cancer Center, which uses a novel
type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple negative breast cancer
(TNBC), the most lethal form of the disease – as well as a vaccine
to prevent ovarian cancer. These vaccine technologies focus on
immunizing against "retired" proteins that have been found to be
expressed in certain forms of cancer. Anixa's unique business model
of partnering with world-renowned research institutions on clinical
development allows the Company to continually examine emerging
technologies in complementary fields for further development and
commercialization. To learn more, visit www.anixa.com or
follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contacts:
Stephen
Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-issuance-of-additional-us-patent-for-ovarian-cancer-vaccine-technology-301945343.html
SOURCE Anixa Biosciences, Inc.